TABLE 3.
Experimental design used in study 2
| Groupa | No. of mice sacrificed in each groupb
|
Total no. of mice | |||
|---|---|---|---|---|---|
| D–32 | D0 | W4 | W8 | ||
| Untreated | 3 | 3 | 5 | 5 | 16 |
| TBI-166 | 5 | 5 | 10 | ||
| INH+RFP+PZA | 5 | 5 + 5 | 15 | ||
| TBI-166+BDQ+LZD | 5 | 5 + 5 | 15 | ||
| TBI-166+BDQ+PMD | 5 | 5 + 5 | 15 | ||
| TBI-166+LZD+PMD | 5 | 5 + 5 | 15 | ||
| Total no. of mice | 3 | 3 | 30 | 50 | 86 |
a
Drugs (abbreviations) and doses: isoniazid (INH), 10 mg/kg; rifampin (RFP), 10 mg/kg; pyrazinamide (PZA), 150 mg/kg; TBI-166 (20 mg/kg); bedaquiline (BDQ), 25 mg/kg; pretomanid (PMD), 100 mg/kg; linezolid (LZD), 100 mg/kg.
b
D, day; W, week.